2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 843

Natriuretic Peptide Predicts Mortality in Systemic Sclerosis
Abstract Number: 1366

Natural Antibodies, Not B Cells, Contribute to Acute Cell Death-Induced Inflammation
Abstract Number: 2710

Necrox-7 Inhibits Cell Aggressiveness By Suppressing of NF-Kappa B Activation and Reactive Oxygen Species Generation in Human Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 167

Negative Gaenslen’s (Squeeze) Test Has a High Negative Predictive Value for Significant Ultrasonographic Metatarsophalangeal Involvement in Early Arthritis
Abstract Number: 2833

Negative Regulator, MiR-23a, Down-Regulated in Psoriatic Arthritis. Implications for Disease Pathogenesis
Abstract Number: 292

Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Abstract Number: 2527

Neonatal Outcome to Paternal Exposures with Anti-Rheumatic Therapy
Abstract Number: 3190

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Abstract Number: 2089

Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions
Abstract Number: 2848

Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Abstract Number: 1451

Neurologic Findings and Serial Neuroimaging in Patients with Linear Scleroderma En Coup De Sabre (ECDS) and Parry-Romberg Syndrome (PRS)
Abstract Number: 761

Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache
Abstract Number: 1434

Neuropathic Pain in Patients with Rheumatoid Arthritis: Relation with Clinical Variables
Abstract Number: 569

Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy
Abstract Number: 964

Neutrophil Extracellular Traps Are Not Only Targets for ACPA-Positive IgG from Rheumatoid Arthritis Patients but Also Directly Trigger Pro- and Anti-Inflammatory Effects Partly Mediated By the C1q Complement Protein

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].